SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathwayXingchen Peng(Sichuan University), Youxue Zhao(Sichuan University)Cell Death and DiseaseMarch 27, 201410.1038/cddis.2014.107Cited by 27SaveCiteExport RISWatch citationsRelated PapersNeoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial|Nature Communications|2025|1